Daiichi Sankyo initiates largest single, double-blind, randomized, Phase III trial for treatment and prevention of recurrent venous thromboembolism
Tokyo, Japan and Edison, N.J. (ots) - First Patient Randomized and Dosed in New Trial with Factor Xa Inhibitor, Edoxaban Daiichi Sankyo Company, Limited (TSE: 4568), announced today that it has initiated a new large-scale pivotal Phase III trial for edoxaban, its investigational oral Factor Xa inhibitor. ...